Physician profile
David Mark Perry
NPI 1770996621
$4,510.60
in general payments reported to CMS, 2019-2025
35 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $204 · 2021: $466 · 2022: $681 · 2023: $680 · 2024: $987 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.61 |
| Education | $392.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $774.80 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $675.43 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $499.36 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $321.34 | 2020-2025 | |
| Lilly USA, LLC | $291.68 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $196.47 | 2021-2025 | |
| Amgen INC. | $189.52 | 2021-2025 | Otezla, Otezla, Enbrel |
| Regeneron Healthcare Solutions, INC. | $177.65 | 2019-2025 | Libtayo, Dupixent |
| Incyte Corporation | $173.28 | 2022-2025 | Opzelura |
| Ucb, INC. | $162.45 | 2019-2025 | Bimzelx |
| Krystal Biotech INC | $119.70 | 2023 | Vyjuvek |
| Leo Pharma INC. | $108.39 | 2019-2024 | Adbry |
| Pfizer INC. | $87.71 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.69 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $74.52 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.47 | 2022-2024 | Sotyktu |
| Almirall LLC | $52.18 | 2025 | Klisyri |
| Organogenesis INC. | $51.94 | 2021-2025 | Affinity |
| Biofrontera INC. | $50.39 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $44.30 | 2024 | Aklief |
| Botanix Sb INC | $41.27 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $36.29 | 2022-2023 | Vtama |
| Paratek Pharmaceuticals, INC. | $30.90 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $28.47 | 2019-2023 | Valchlor |
| Strata Skin Sciences, INC. | $24.19 | 2025 | Xtrac |
| Journey Medical Corporation | $21.11 | 2022 | |
| Nabriva Therapeutics, Plc | $18.83 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $18.54 | 2025 | Opsynvi, Uptravi |
| Verrica Pharmaceuticals INC. | $17.49 | 2024 | Ycanth |
| Portola Pharmaceuticals, LLC | $16.02 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.68 | 2025 | Spevigo |
| Mission Pharmacal Company | $14.89 | 2020 | |
| Encore Dermatology INC. | $12.96 | 2020 | |
| Phadia US INC. | $12.79 | 2019 | |
| Merck Sharp & Dohme LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.